



Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor

Angela Joubert James¹ · Catherine C. Smith² · Mark Litzow³ · Alexander E. Perl⁴ · Jessica K. Altman⁵ · Dale Shepard⁶ · Takeshi Kadokura⁷ · Kinya Souda⁷ · Melanie Patton¹ · Zheng Lu¹ · Chaofeng Liu¹ · Selina Moy¹ · Mark J. Levis⁸ · Erkut Bahceci¹

Published online: 23 July 2021
© The Author(s) 2021

Correction to:
Clinical Pharmacokinetics (2020) 59:1273–1290
<https://doi.org/10.1007/s40262-020-00888-w>

In Table 8 of this article, the data in the column headed “Fed Geometric LS Mean” were mistakenly listed under column heading “Fasted Geometric LS Mean” and vice versa.

The correct Table 8 is as follows:

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

Table 8 Effects of food on the pharmacokinetic (PK) profile of gilteritinib

PK parameter	N	Fasted GLSM	Fed GLSM	GMR (%) ^a	90% CI (%) ^a
AUC _{inf} (ng•h/mL)	16	1900	1780	93.8	81.2–108.4
AUC _{last} (ng•h/mL)	16	1840	1740	94.6	81.8–109.3
AUC ₇₂ (ng•h/mL)	16	951	865	91.0	78.2–105.9
C _{max} (ng/mL)	16	28.6	21.2	74.0	62.2–88.1

AUC₇₂ area under the concentration–time curve from the time of dosing to 72 h post-dose, AUC_{inf} area under the concentration–time curve from the time of dosing extrapolated to time infinity, AUC_{last} area under the concentration–time curve from the time of dosing to the last measurable concentration, CI confidence interval, C_{max} maximum observed concentration, GLSM geometric least-squares mean, GMR geometric mean ratio

^aAssessment based on an analysis of variance performed on natural log-transformed parameters with the food condition as a fixed effect. Ratios and confidence limits are transformed back to raw scale and values are expressed as percentages. The ratio denotes the gilteritinib 40-mg fed GLSM estimate divided by the gilteritinib 40-mg fasted GLSM estimate

The original article can be found online at <https://doi.org/10.1007/s40262-020-00888-w>.

✉ Angela Joubert James
angela.james@astellas.com

¹ Astellas Pharma US, Inc., 1 Astellas Way, Northbrook, IL 60062, USA

² University of California San Francisco, San Francisco, CA, USA

³ Mayo Clinic, Rochester, NY, USA

⁴ University of Pennsylvania-Abramson Comprehensive Cancer Center, Philadelphia, PA, USA

⁵ Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA

⁶ Cleveland Clinic, Cleveland, OH, USA

⁷ Astellas Pharma, Inc., Tokyo, Japan

⁸ John Hopkins University, Baltimore, MD, USA